- Home
- YALA vs AUPH Comparison
YALA vs AUPH Comparison
Compare YALA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YALA
- AUPH
- Stock Information
- Founded
- YALA 2016
- AUPH 1993
- Country
- YALA United Arab Emirates
- AUPH Canada
- Employees
- YALA N/A
- AUPH N/A
- Industry
- YALA Computer Software: Programming Data Processing
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- YALA Technology
- AUPH Health Care
- Exchange
- YALA Nasdaq
- AUPH Nasdaq
- Market Cap
- YALA 1.1B
- AUPH 999.8M
- IPO Year
- YALA 2020
- AUPH 1999
- Fundamental
- Price
- YALA $6.70
- AUPH $7.96
- Analyst Decision
- YALA
- AUPH Strong Buy
- Analyst Count
- YALA 0
- AUPH 2
- Target Price
- YALA N/A
- AUPH $11.50
- AVG Volume (30 Days)
- YALA 1.3M
- AUPH 1.3M
- Earning Date
- YALA 05-19-2025
- AUPH 07-31-2025
- Dividend Yield
- YALA N/A
- AUPH N/A
- EPS Growth
- YALA 8.53
- AUPH N/A
- EPS
- YALA 0.77
- AUPH 0.27
- Revenue
- YALA $344,824,034.00
- AUPH $247,295,000.00
- Revenue This Year
- YALA $9.21
- AUPH $12.15
- Revenue Next Year
- YALA $5.98
- AUPH $18.31
- P/E Ratio
- YALA $8.96
- AUPH $29.47
- Revenue Growth
- YALA 6.40
- AUPH 29.20
- 52 Week Low
- YALA $3.71
- AUPH $5.15
- 52 Week High
- YALA $8.29
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- YALA 41.43
- AUPH 46.96
- Support Level
- YALA $6.91
- AUPH $7.77
- Resistance Level
- YALA $8.15
- AUPH $8.58
- Average True Range (ATR)
- YALA 0.45
- AUPH 0.31
- MACD
- YALA -0.17
- AUPH -0.03
- Stochastic Oscillator
- YALA 35.90
- AUPH 43.89
About YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The Group has one operating segment, which is the social networking and entertainment platform.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.